Gilead Sciences, Inc. announced Phase 2 clinical trial results showing that its investigational "Quad" regimen of elvitegravir, cobicistat and Truvada for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks.
Biosimilars now have a regulatory pathway, but are the directions to approval clear?
A host of new and exciting technologies are providing researchers with an explosion of molecular biological data. Yet, the number of new drugs entering the market is stagnating and about 90% of the compounds entering into preclinical development fail to reach the market.
Genetic variations—the way in which genes and proteins differ between individuals—can have important medical consequences. As a result, complete human genome sequencing has many potential drug discovery applications.
The three current NGS platforms share a common feature—massively parallel sequencing of spatially separated, clonally amplified DNA molecules. This is fundamentally different than Sanger technology, in which individual sequencing reactions are separated by capillary electrophoresis.
Genomic studies combined with individual testing enables researchers to determine a patient's susceptibility to disease, predict how they will respond to a particular drug, and match them with the right therapeutics.
Researchers are constantly searching for a better understanding of fundamental disease mechanisms and tools for early diagnosis and even pre-diagnosis of disease.
The advent of high-throughput DNA sequencing and the completion of the Human Genome Project was supposed to usher in the era of personalized medicine, where the treatment of disease could be tailored toward one’s genetic predispositions.
Cellexus Limited offers the CellMaker PLUS single-use disposable bioreactor system, which was designed for efficient growth of the widest range of cell types.
Virtify, Inc. announced the upcoming release of its new software product Virtify PIM Enterprise, part of the Virtify Enterprise Content Compliance (ECC) Software Suite.
Air Science has introduced its NEW Purair ECO line of energy-saving ductless fume hoods designed for both chemical and particulate protection over a broad range of laboratory applications. It is available with a choice of controllers.
Federal health officials said Tuesday that an experimental diet drug produced minimal weight loss while raising safety questions about its effects on the heart, sending shares of its developer Arena Pharmaceuticals plummeting in morning trading.
The Alzheimer’s Drug Discovery Foundation has awarded a grant of $244,500 to AgeneBio Inc. to develop a new class of small-molecules that have promise in treating amnestic mild cognitive impairment, a neurological condition that often progresses to Alzheimer’s disease.
Amorcyte, Inc., has been granted the first U.S. patent for a chemotactic hematopoietic stem cell product, its delivery and the cell potency and stability needed to treat the consequences of a vascular injury.
Genmab A/S, Copenhagen and Seattle Genetics, Inc. have entered into an antibody-drug conjugate (ADC) research collaboration agreement.